SCHEMBL392216

SCHEMBL392216

Cc1cc(C)cc(C(=O)OCOC(=O)N(CC(=O)OCc2ccccc2)C(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
KMT2A Q03164 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 5/20 0.39
MAPK1 P28482 1/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.36
TACR1 P25103 1/20 0.35
JMJD6 Q6NYC1 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL394173 0.90 MAPT (0.47) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL390169 0.88 ALDH1A1 (0.37) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL393666 0.87 KMT2A (0.43) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL393566 0.86 MAPK1 (0.50) TDP1KMT2ASLC6A3MAPTALDH1A1
SCHEMBL395726 0.86 KMT2A (0.48) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL392819 0.86 MAPT (0.49) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL393185 0.85 MAPT (0.41) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL395276 0.85 MAPT (0.45) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL393109 0.85 KMT2A (0.44) TDP1KMT2ASLC6A2SLC6A3MAPT
SCHEMBL393493 0.85 MAPT (0.45) TDP1KMT2ASLC6A2SLC6A3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP claimed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO claimed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US claimed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 TDP1 4661/4885KMT2A 2161/4885SLC6A2 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.